Naibec Announces Primate Brain Transmission Efficacy of BBB Shuttle Platform at International Conference

Naivek announced on the 10th that it attended the 6th ‘CNS Drug Delivery Summit’ held in the United States and presented a poster on the brain delivery effects of its peptide-based ‘Blood-Brain Barrier (BBB)’ shuttle platform ‘PEPTARDEL-TB’ in non-human primate experiments. Along with this, meetings were held for collaboration with numerous global pharmaceutical companies such as Biogen, Eli Lilly, Takeda, and Ionis Pharmaceuticals.

PEPTARDEL-TB is a customizable shuttle applicable to LDL receptors and various other receptors for different diseases. Its peptide structure is not complex, making it easy to produce, and it allows faster application compared to antibody-based targeted therapeutics. The company explained that by optimizing the binding sites with receptors when applying this platform, it promotes permeability without interfering with the inherent functions of the receptors, thus offering superior safety.

PEPTARDEL-TB targets LDL receptors and others to assist drug penetration through the blood-brain barrier. Therapeutics linked to the platform were confirmed to remain in the deep cortex of the brain longer than when unlinked. It was observed to stay in the cerebrospinal fluid (CSF) for more than 15 days after a single administration, demonstrating its efficacy as a delivery vehicle.

At this summit, global pharmaceutical companies expressed great interest in PEPTARDEL-TB, a disease-specific customizable blood-brain barrier shuttle. In particular, they focused on whether PEPTARDEL-TB could be applied to enhance brain delivery efficiency of gene therapeutics such as siRNA and ASO (AntiSense Oligonucleotide).

Global pharmaceutical companies requested data from Naivek on PEPTARDEL-TB’s blood half-life, drug retention time in the brain, and drug distribution. They inquired whether there were comparative data based on the gene drug loading method (chemical bonding or nanoparticle formulation) and also requested detailed information on the receptor sequence sites to which PEPTARDEL-TB binds.

A Naivek representative said, “Through this summit, we introduced the superior efficacy of PEPTARDEL-TB compared to existing delivery vehicles to the global market and confirmed the utility of the platform technology through in-depth meetings with pharmaceutical companies focused on brain disease research. We have sent poster materials and related data to several global pharmaceutical companies and plan to present the requested data at the ‘JP Morgan Conference’ in January next year.”

He added, “Since PEPTARDEL-TB targets multiple receptors, it is a flexible platform design applicable to various brain diseases. We have achieved meaningful results by applying PEPTARDEL-TB to effective gene and protein therapeutics for brain metastases and Alzheimer’s disease, and we plan to focus on research and development for combination therapy and technology transfer with global pharmaceutical companies.”

The CNS Summit is an international academic event that shares the latest research and innovations to improve drug delivery and therapeutic technologies for central nervous system diseases, especially Alzheimer’s disease and Parkinson’s disease. The summit discusses technologies and drug delivery platforms addressing the critical blood-brain barrier challenges in treating central nervous system-related diseases. This year, it was held in Boston, USA, from the 3rd to the 5th of this month.